Why the study?
Venous thromboembolism in pregnancy is a major factor of maternal mortality, presenting challenges in distinguishing physiologic changes from symptoms and balancing the risks and benefits of anticoagulation.
Systemic anticoagulation remains the cornerstone of VTE management in pregnancy, requiring careful balance of maternal and fetal risks.
Answers are grounded in this paper and cite their sources.
May guide anticoagulation decisions for pregnancy-associated VTE; leaves open need for prospective validation of strategies.
Venous thromboembolism (VTE) in pregnancy, consisting of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a major factor of maternal mortality. Several patient-specific risk factors along with the physiologic changes of pregnancy promote a state of hypercoagulability in pregnant women. Detailed assessment of all pregnant women can establish a risk profile that would guide clinical decisions, and balance potential therapeutic benefits with side effects. Differentiating between physiologic changes of pregnancy and symptoms of VTE can be challenging and warrants meticulous clinical evaluation. Timely and accurate diagnosis of VTE with proper imaging is essential for its management, and systemic anticoagulation remains the cornerstone of VTE prevention and therapy. Furthermore, advanced invasive treatment options such as inferior vena cava filters and thrombectomy can be considered for complex cases. Importantly, the risk of systemic anticoagulation should be balanced against the risk of VTE-associated morbidity and mortality for mother and fetus, and an informed decision should be made. In this review, we present an up-to-date overview of VTE management in pregnancy and the postpartum period.
No takes yet. Share an insight, caveat, or question.
Kalaitzopoulos et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: